Research from industry analyst GlobalData suggests that German company BioNTech (Nasdaq: BNTX) will likely be a leader in the emerging market for mRNA-based oncology therapies.
The global market for mRNA-based treatments in cancer is expected to reach $2 billion by the end of the decade, with BioNTech set to generate almost half of that amount.
Following on from its extraordinary success with the development of the Comirnaty vaccine, targeting the novel coronavirus in partnership with Pfizer (NYSE: PFE), the firm now has multiple drugs in all stages of development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze